AT1 receptor binding protein activation strategy in the treatment of hypertension and related organ injury

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18010
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54040:Metabolism and endocrinology-related
• Research Institution: Yokohama City University
• Principal Investigator: KOBAYASHI Ryu 横浜市立大学, 医学部, 客員研究員 (60805612)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 慢性腎臓病 / 高血圧 / レニン-アンジオテンシン系

Outline of Final Research Achievements

We have previously shown that ATRAP (angiotensin II receptor; associated protein; Agtrap) interacts with AT1R (angiotensin II type 1 receptor) and promotes constitutive internalization of AT1R so as to inhibit hyperactivation of its downstream signaling. ATRAP deficiency in proximal tubules did not exacerbate angiotensin-dependent hypertension in vivo. The results indicate that renal proximal tubule ATRAP has a minor role in angiotensin-dependent hypertension in vivo.

Free Research Field

慢性腎臓病

Academic Significance and Societal Importance of the Research Achievements

腎尿細管で高発現しているATRAPの活性化を行うことで，高血圧治療及び慢性腎臓病などの腎疾患における新たな分子標的治療実現のための検討を行うことを目的とする．

特に慢性腎臓病については，現時点で特効薬がない疾患でありながら患者は増加の一途をたどっており，病態改善に寄与する治療が実現できれば，社会的意義は大きいと考える．